About Lodo Therapeutics
Lodo Therapeutics is a Healthcare company based in New York (United States) founded in 2015 by Sean Brady, and was acquired by Zymergen in May 2021. Developer novel therapeutics to treat resistant infectious diseases and cancers using AI. Lodo Therapeutics has raised $19.87 million across 1 funding round from investors including AbbVie, Lilly and ARE. The company has 24 employees. Lodo Therapeutics has completed 2 acquisitions, including Conifer Point and Hibiskus. Lodo Therapeutics offers products and services including AI Models, Data Generation, and Lab Automation. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is LODO THERAPEUTICS CORPORATION. Its competitors include Insmed, Affinivax and Symbiomix Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Lodo Therapeutics was founded in 2015 and is based in New York, United States. Operations center on the biotech sector, where a metagenomics-driven platform is employed for discovering, biosynthesizing, and characterizing genetically encoded small molecules from microbial sources. Microbiome-derived pharmaceutical products are identified, with a focus on treatments for resistant infectious diseases, cancers, and tuberculosis.
- Headquarters New York, United States
- Employees 24
- Founders Sean Brady
- Stage Acquired
- SectorsHealthcare
- Website lodotherapeutics.com
- Social LinkedIn
- Acquired by Zymergen (May 2021)
- Legal Name Lodo Therapeutics Corporation
- Total Equity Funding$19.87M (USD)
in 1 rounds
- Latest Funding Round$19.87M (USD), Series A
Jan 2017
- InvestorsAbbVie
& 13 more
- Employee Count24
- Investments & AcquisitionsConifer Point
& 1 more
- Acquired byZymergen
(May 2021)
Products & Services of Lodo Therapeutics
Lodo Therapeutics offers a comprehensive portfolio of products and services, including AI Models, Data Generation, and Lab Automation.
Provides fine-tuning for AI in biotechnology research
Generates high-quality datasets for R&D applications
Offers hardware and software for efficient lab processes
Funding Insights of Lodo Therapeutics
Lodo Therapeutics has successfully raised a total of $19.87M through 1 strategic funding round. The most recent funding activity was a Series A round of $19.87 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.87M
- Total Rounds 1
- Last Round Series A β $19.87M
- First Round $19.87M
(Jan 2017)
- Investors Count 13
All 1 funding rounds of Lodo Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $19.87M | Series A | β | β |
14 investors in total: 14 institutional.
Investors in Lodo Therapeutics
Lodo Therapeutics has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, Lilly and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Economic growth is supported via family-backed investments in New York. | 1768 | pfnyc.org | New York, United States | |
VC firm funding companies in the US | 1981 | 180degreecapital.com | Montclair, United States | |
Venture capital services are offered for early-stage biotech companies. | acceleratorlsp.com | Seattle, United States | ||
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | abbvie.com | Chicago, United States | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
| jnjinnovation.com | ||||
Develops and manufactures APIs, finished dosage forms, and biologics. | 2000 | wuxipharmatech.com | Shanghai, China | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for Lodo Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lodo Therapeutics
13 people are tracked at Lodo Therapeutics (6 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 24.
| Name | Role | Group |
|---|---|---|
Sean Brady | Co-Founder | Leadership |
Subodh S. Deshmukh | Chief Development Officer | Leadership |
Jay Flatley | Chairman & Acting CEO | Leadership |
Enakshi Singh | CFO | Leadership |
Lincoln Germain | Chief Commercial Officer | Leadership |
Dmitriy Ryaboy | CTO | Leadership |
Sandi Peterson | Lead Independent Director | Board & advisors |
Travis Murdoch | Director | Board & advisors |
Christine Gorjanc | Director | Board & advisors |
Steven Chu | Director | Board & advisors |
Matt Ocko | Director | Board & advisors |
Rohit Sharma | Director | Board & advisors |
Devin Scannell | SVP, Drug Discovery | Team |
Complete people profiles for Lodo Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lodo Therapeutics
Lodo Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Conifer Point and Hibiskus.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small-molecule therapeutics for cancer are developed by Hibiskus. | hibiskusbio.com | Kalamazoo, United States | 2017 | Sep 2020 | β’β’β’β’ | |
New drugs are developed using custom fragment-based design software. | coniferpoint.com | Doylestown, United States | 2015 | Aug 2020 | β’β’β’β’ |
Complete acquisition details for Lodo Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lodo Therapeutics
5 dated milestones of Lodo Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Lodo Therapeutics is founded.
- Funding First funding round of $19.9M.
- Acquisition Acquires Conifer Point.
- Acquisition Acquires Hibiskus.
- Exit Acquired by Zymergen.
Competitors of Lodo Therapeutics
Lodo Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Insmed, Affinivax and Symbiomix Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | 912 | Developer of small molecule inhibitors for rare lung diseases | ||
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| symbiomix.com | 2012 | Newark, United States | $66.55M | Late-stage biopharma antibiotics for gynecological infections are developed. |
Detailed competitors of Lodo Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Lodo Therapeutics (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lodo Therapeutics
Complete news archive for Lodo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lodo Therapeutics
Lodo Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Lodo Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Lodo Therapeutics is a funded company, having raised a total of $19.87M across 1 funding round to date. The company's 1st funding round was a Series A of $19.87M, raised on Jan 2017.
Lodo Therapeutics has 24 employees.
Lodo Therapeutics was founded in 2015 and is based in New York, United States. Operations center on the biotech sector, where a metagenomics-driven platform is employed for discovering, biosynthesizing, and characterizing genetically encoded small molecules from microbial sources. Microbiome-derived pharmaceutical products are identified, with a focus on treatments for resistant infectious diseases, cancers, and tuberculosis.
Lodo Therapeutics's top competitors include Insmed, Affinivax and Symbiomix Therapeutics.
Lodo Therapeutics offers AI Models, Data Generation, and Lab Automation.
Lodo Therapeutics has made 2 acquisitions, including Conifer Point, and Hibiskus.
Lodo Therapeutics has 14 investors. Key investors include AbbVie, Lilly, ARE, New York State, and Zymergen.
Lodo Therapeutics operates through Lodo Therapeutics Corporation.
Yes. Lodo Therapeutics was acquired by Zymergen in May 2021.

